SAM
AKYA

Silvercrest Asset Management’s Akoya BioSciences AKYA Stock Holding History

Silvercrest Asset Management’s Portfolio AKYA Stock Details AKYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-580,834
Closed -$2.72M – 901
2024
Q1 		$2.72M Buy
+580,834
New +$3.02M 0.02% 466

Other funds holding AKYA

BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Silvercrest Asset Management's AKYA Position: Q2 2024 in Review

Silvercrest Asset Management sold out of Akoya BioSciences (AKYA) in Q2 2024, closing a stake of 580,834 shares — an estimated $2.72M sold.

Silvercrest Asset Management first reported a position in AKYA in Q1 2024 and held it in 1 quarter. The position peaked at $2.72M in Q1 2024. 59 funds tracked by Wall St. Rank hold AKYA as of Q2 2024.

  • Silvercrest Asset Management reported no remaining Akoya BioSciences position as of Q2 2024 after selling out during the quarter.
  • Silvercrest Asset Management sold 580,834 Akoya BioSciences shares in Q2 2024, an estimated $2.72M.
  • Silvercrest Asset Management first reported a position in Akoya BioSciences in Q1 2024 and held it in 1 quarter.
  • Silvercrest Asset Management's Akoya BioSciences position peaked at $2.72M in Q1 2024.
  • 59 funds tracked by Wall St. Rank held Akoya BioSciences as of Q2 2024.

Based on Silvercrest Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.